Infliximab: Mechanism of action beyond TNF-α neutralization in inflammatory bowel disease

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 7, 2004, Pages 639-641

  Kirman, Irena ^a   Whelan, Richard L ^a   Nielsen, Ole H ^b  

^a Howard Hughes Medical Institute   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Crohn's disease; Granulocyte macrophage colony stimulating factor; Infliximab; T cells

Indexed keywords

ADALIMUMAB; CHIMERIC ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; NEUTRALIZING ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

APOPTOSIS; ARTICLE; AUTOIMMUNITY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; ENTERITIS; HUMAN; INFLAMMATION; MUCOSA CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3142559655     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.meg.0000108345.41221.c2     Document Type: Article

References (23)

1. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
2. Dalwadi H, Wei B, Kronenberg M, Sutton CL, Braun J. The Crohn's disease-associated bacterial protein 12 is a novel enteric T cell superantigen. Immunity 2001; 15:149-158.
3. Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002; 169:5308-5314.
4. Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, et al. IBD-like enteritis and caecitis in a senescent accelerated mouse P1/Yit strain. Gut 1998; 43:71.
5. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997; 150:823-832.
6. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159:6276-6282.
7. Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, Muller W, et al. T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996; 184:241-251.
8. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001; 107: 695-702.
9. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994; 1:553-562.
10. Kontoyiannis D, Boulougouris G, Manoloukos M, Armaka M, Apostolaki M, Pizarro T, et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002; 196:1563-1574.
11. Nikolaus S, Raedler A, Kuhbacker T, Sfikas N, Folsch UR, Schreiber S. Related mechanisms in failure of infliximab for Crohn's disease. Lancet 2000; 356:1475-1479.
12. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001; 15:212-222.
13. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50:206-211.
14. Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO and Dahlerup JF. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment. Eur Jrnl Gastroenterol Hepatol 2004; 16:649-655.
15. Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, et al. Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51:675-686.
16. Biondo M, Nasa Z, Marshall A, Toh BH, Alderuccio F. Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J Immunol 2001; 166:2090-2099.
17. Noguchi M, Hiwatashi N, Liu ZX, Toyota T. Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion 2001; 63 (suppl 1):32-36.
18. Ina K, Kusugami K, Hosokawa T, Imada A, Shimizu T, Yamaguchi T, et al. Increased mucosal production of granulocyte colony-stimulating factor is related to a delay in neutrophil apoptosis in inflammatory bowel disease. J Gastroenterol Hepatol 1999; 14:46-53.
19. Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360:1478-1480.
20. Shibuya A, Taguchi K, Kojima H, Abe T. Inhibitory effect of granulocyte-macrophage colony-stimulating factor therapy on the generation of natural killer cells. Blood 1991; 78:3241-3247.
21. Esnault S, Malter JS. Extracellular signal-regulated kinase mediates granulocyte-macrophage colony-stimulating factor messenger RNA stabilization in tumor necrosis factor-alpha plus fibronectin-activated peripheral blood eosinophils. Blood 2002; 99:4048-4052.
22. Capowski EE, Esnault S, Bhattacharya S, Malter JS. Y box-binding factor promotes eosinophil survival by stabilizing granulocyte-macrophage colony-stimulating factor mRNA. J Immunol 2001; 167:5970-5976.
23. Hachiya M, Koeffler HP, Suzuki G, Akashi M. Tumor necrosis factor and interleukin-1 synergize with irradiation in expression of GM-CSF gene in human fibroblasts. Leukemia 1995; 9:1276-1281.